Warfarin purple toe

An anticoagulant Warfarin (Coumadin) is a blood thinner medication. Less common side effects are purple toe syndrome and tissue death. Warfarin and thus

Purple toe syndrome is a recognised adverse effect of warfarin therapy. The literature has described resolution of the ischaemic symptoms on

Warfarin and heparininduced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Most patients with this

Rare cases of purple toe syndrome, warfarin-induced skin necrosis, and there are reports of calciphylaxis with warfarin therapy. Purple toe syndrome is a complication characterized by cholesterol microembolization that causes purple lesions to develop on the toes and sides of the feet. Purple toe syndrome usually develops 3 to 8 weeks after the

Fig. 1. Purple discoloration of toes persists after warfarin was stopped (For interpretation. Fig. 2. Plantar aspect of both feet shows predominantly dusky toes

Warfarin can, in rare instances, cause violaceous painful discoloration of the toes and the sides of the feet, referred to as the purple

Purple toes syndrome is an extremely uncommon, nonhemorrhagic, cutaneous complication associated with warfarin therapy. It is characterized by the sudden appearance of bilateral, painful, purple lesions on the toes and sides of the feet that blanch with pressure.

by DR Ryu Cited by 5Purple toe syndrome is an extremely rare complication of warfarin therapy. The occurrence of purple toe syndrome is characterized by a sudden appearance

A patient who developed purple toes after 1 year of warfarin therapy was encountered, and fondaparinux was substituted with prompt resolution of all his symptoms and this is the first case describing late onset purple toe syndrome with warFarin with successful substitution with fondAParinux. Purple toe syndrome is a rarely reported adverse effect of warfarin. In all described cases, the